Grants and Contributions:
Title:
Proof of concept study for combinations of tetrodotoxin (TTX) and current analgesics in chemotherapy pain management and the development of new formulations of TTX
Agreement Number:
870447
Agreement Value:
$328,984.00
Agreement Date:
Aug 1, 2016 - Jul 31, 2019
Description:
This project will attempt to demonstrate the synergistic effects of tetrodotoxin (TTX) and current analgesics for the treatment of chemotherapy induced peripheral neuropathy. A new TTX formulation will be developed that can be combined with currently available analgesics for a synergistic analgesic effect at a subsequent stage.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6E 4A6
Reference Number:
172-2018-2019-Q1-870447
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
104030796
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 181 days. The total amended value is 91,160 dollars.
Amendment Date
Jan 11, 2019
Recipient's Legal Name:
WEX Pharmaceuticals Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: